InvestorsHub Logo

Echo20

08/25/16 11:46 AM

#157496 RE: runninggirl2016 #157495

Running girl

Good point for K and p53 for heart repair. That could mean millions a year for CTIX.

Echo20

frrol

08/25/16 11:54 AM

#157498 RE: runninggirl2016 #157495

Yes this is a job for an MDM2 inhibitor since the problem is not p53 mutation. Which is why this study uses RITA, an MDM2 inhibitor. Kevetrin may be effective here if its theorized MDM2-phosphorylation properties hold up, which would be exciting.

F1ash

08/25/16 12:50 PM

#157506 RE: runninggirl2016 #157495

Very interesting. Have you sent that to Cellceutix?
The CEO appears to be receptive to following up on worthwhile due diligence provided by shareholders. It's not entirely out of the question that they might feel your find is worth further investigation.
Thanks for sharing.

AlanC

08/25/16 6:45 PM

#157534 RE: runninggirl2016 #157495

FINRA short sales of CTIX
20160825|CTIX|50495|0|188449|O
27% of today's volume was short sales!
Go CTIX!!!